Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003.
about
Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia.Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing invasive diseases from Shenzhen Children's HospitalSusceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study.Drug susceptibility testing of clinical isolates of streptococci and enterococci by the Phoenix automated microbiology system.Reporting Emerging Resistance of Streptococcus pneumoniae from India.Macrolide susceptibility and serotype specific macrolide resistance of invasive isolates of Streptococcus pneumoniae in Germany from 1992 to 2008Comparison of transformation frequencies among selected Streptococcus pneumoniae serotypes.The comparative development of elevated resistance to macrolides in community-acquired pneumonia caused by Streptococcus pneumoniae.Molecular Investigation of Quinolone Resistance of Quinolone Resistance-Determining Region in Streptococcus pneumoniae Strains Isolated from Iran Using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism Method.Molecular characterization of non-penicillin-susceptible Streptococcus pneumoniae in NorwayClonal spread of mef-positive macrolide-resistant Streptococcus pneumoniae isolates causing invasive disease in adults in GermanyPrevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in KoreaPneumococcal sepsis in patients with systemic lupus erythematosus.Global fluoroquinolone resistance epidemiology and implictions for clinical use.Pneumococcal virulence gene expression and host cytokine profiles during pathogenesis of invasive disease.Insight Into Resistance Phenotypes of Emergent Non 13-valent Pneumococcal Conjugate Vaccine Type Pneumococci Isolated From Invasive Disease After 13-valent Pneumococcal Conjugate Vaccine Implementation in France.Severe community-acquired pneumonia in adults: current antimicrobial chemotherapy.Therapy of community-acquired acute bacterial meningitis: the clock is running.Levofloxacin in the treatment of community-acquired pneumonia.Elderly patients with community-acquired pneumonia: optimal treatment strategies.Bacterial meningitis: current therapy and possible future treatment options.Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapyAntibiotic Resistant Superbugs: Assessment of the Interrelationship of Occurrence in Clinical Settings and Environmental Niches.Clinical features of bacterial meningitis in Italy: a multicenter prospective observational study.Antimicrobial susceptibility trends among Streptococcus pneumoniae over an 11-year period in an Iranian referral children Hospital.Implementation of a Meningitis Care Bundle in the Emergency Room Reduces Mortality Associated With Acute Bacterial Meningitis.Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.Streptococcus pneumoniae choline-binding protein E interaction with plasminogen/plasmin stimulates migration across the extracellular matrix.Rapid screening of fluoroquinolone resistance determinants in Streptococcus pneumoniae by PCR-restriction fragment length polymorphism and single-strand conformational polymorphism.Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacinAdvances in pneumococcal antibiotic resistance.Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain.Emergence of a unique multiply-antibiotic-resistant Streptococcus pneumoniae serotype 7B clone in Dhaka, Bangladesh.Prevalence and macrolide resistance phenotypes and genotypes among clinical isolates of Streptococcus pneumoniae collected in Sofia, Bulgaria from 2001 to 2005.Molecular characterization of invasive penicillin non-susceptible Streptococcus pneumoniae from Denmark, 2001 to 2005.Serotype 3 is a common serotype causing invasive pneumococcal disease in children less than 5 years old, as identified by real-time PCR.Streptokokken — ein Überblick
P2860
Q24815187-AF9DE663-029E-47AC-865C-9515B65B6BF0Q28534411-3C79D2AD-7C18-4895-A27B-E0FADFF9FF7BQ31139606-719F773C-55E0-4405-890B-AC82D25D937FQ33285554-F262CA7C-7F7F-41D9-B82A-6B2DC37A4697Q33736494-48079427-36FB-41D0-B27F-21FD6073A779Q33756049-83E00CF5-22F6-4D4C-A9C1-AD7B59988F65Q33987031-233463D5-1866-4D0A-97B1-CF1161FE3BC0Q34353808-43DF1A19-0DC1-49E0-94D3-11C76F3DDB91Q34478323-A49DA9CC-71F2-4DAC-952F-A0A42CE57E49Q35073387-682EE4BF-F91F-4DBB-BC6C-087A0EBB89F6Q35759018-1D8810FB-D769-471E-AC37-723CFB6F3804Q35879084-9DC5D5AA-8F50-42CA-8C67-3C451611C139Q36334477-81078A17-95CF-4C6D-A82F-AAF7A3612C80Q36337074-B06E3BEC-9D2F-432F-84FA-37358388412FQ36421548-3958340F-0B8C-4841-906B-D0D4BB9DCF17Q36650547-0C62CA42-B78A-44F4-8914-A4F5CAA7C579Q37557686-625CEC57-156E-4E9A-B128-025EBF9CFFBCQ37614552-BCDEA4EA-5854-4536-B668-91620F98ABCBQ37747381-EB9813E8-1735-4859-BCE3-B40613B145BFQ37896600-6CE47C75-8D55-4E3C-9287-E6F5BC27314EQ37949641-1165B4AB-2FDE-4FAF-8F13-AE8F6D7F83A6Q37998398-DCF3F039-ED0C-41E1-A2BC-8B3E590C1C4AQ38842229-C8125203-BB22-464F-AF5A-7F9755BEAF68Q39062989-B489AB83-2E15-48C4-BBFC-903FB6E6DDD5Q39164030-E2B9356E-AAA1-4EC9-A186-59C0CBF6F3E6Q39993687-5AF53CF5-3CA1-428E-A743-D90B85936641Q41143802-2B32BFB8-0EAA-40CB-BCDA-6472E79CE877Q41854694-D9C95682-AF9B-4603-908A-332DB2188E3AQ41911205-0CD3A85B-2E63-4EE5-ADAB-C43B1373AB56Q42041266-79F5E7C6-A5AF-4FE2-9222-A2AA254D0AFFQ42078632-669FA890-3358-46AB-8833-4E1D4A840AD1Q42243746-40AABE32-6595-4D87-B527-CC0201442F9EQ43069250-6237A1AE-E779-435E-880E-1C3F77FF4485Q43124655-5E36356C-9DC0-4116-B465-82068FC7CCD5Q43928503-E846837F-92F5-4FC9-AD0B-2EFE1259709DQ50550639-12836E36-A61D-4EEA-9C62-2A50AEA5ED1DQ54340857-01439ED8-9CCC-4D0D-8938-1CEDD435F550Q56637772-2FD6F4AD-C862-4D50-8B32-B69E55385751
P2860
Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Antimicrobial susceptibility o ...... n countries from 2001 to 2003.
@ast
Antimicrobial susceptibility o ...... n countries from 2001 to 2003.
@en
type
label
Antimicrobial susceptibility o ...... n countries from 2001 to 2003.
@ast
Antimicrobial susceptibility o ...... n countries from 2001 to 2003.
@en
prefLabel
Antimicrobial susceptibility o ...... n countries from 2001 to 2003.
@ast
Antimicrobial susceptibility o ...... n countries from 2001 to 2003.
@en
P2093
P2860
P1476
Antimicrobial susceptibility o ...... n countries from 2001 to 2003.
@en
P2093
Adnan Al-Lahham
Mark van der Linden
Murat Y Cil
Peter Appelbaum
Ralf René Reinert
Susanne Reinert
P2860
P304
P356
10.1128/AAC.49.7.2903-2913.2005
P407
P577
2005-07-01T00:00:00Z